Digital self-management for fibrotic lung disease
Part of Lungs & breathing clinical trials.
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosis of a scarring lung disease called fibrotic interstitial lung disease.
- Own a smartphone or tablet and have an email address.
- Be comfortable using apps or the internet on your device.
- Your lung treatment must be stable (no big changes) for the past 30 days.
- You must be able to understand and speak English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study sets up an international registry to follow people with newly diagnosed fibrotic interstitial lung disease (lung scarring). It uses eHealth technology (an online/app-based system) so your team can better understand your condition over time and improve future care.
This trial studies whether using a home monitoring program helps people with pulmonary fibrosis track their condition. It aims to make care easier and catch changes early.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
This study compares a smartphone app called FORTISKAP™ that reminds you to take your medications versus standard care. The trial includes people with interstitial lung disease (a scarring condition of the lungs), sarcoidosis (an inflammatory condition), or pulmonary hypertension (high blood pressure in the lungs), and aims to see if the app helps people take their medications more reliably.
This trial tests a smartphone-based program to help people with COPD manage their condition at home. It may help you track symptoms and avoid flare-ups.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.